CONNECT WITH US
HealthTech

HealthTech

Medtronic’s Hugo robot gets expanded FDA clearance in general surgery

MedTech Dive logo

Published on

Add as a preferred source on Google
Medtronic’s Hugo robot gets expanded FDA clearance in general surgery

The specialties gaining authorization account for more than half of the soft tissue procedures performed annually in the U.S.

Hugo received its initial FDA clearance in December for urologic procedures such as prostate removal, becoming the first large medtech company to bring a robotic soft tissue platform to the U.S. market since Intuitive launched the da Vinci system in 2000.

Johnson & Johnson soon followed Medtronic with FDA authorization in July for the Ottava system in general surgery, and last month, Stryker unveiled an agreement to distribute CMR Surgical’s Versius soft tissue robot in the U.S.

As it pushes into robotic procedures, Medtronic is looking to leverage its deep expertise in general surgery. The latest FDA clearance extends Hugo’s reach into specialties where Medtronic instruments have been used in open and laparoscopic surgery for decades, the company said. Surgeons can use Medtronic technology including the LigaSure vessel-sealing instrument in their robotic cases.

A growing number of U.S. hospitals are using the Hugo robot, Medtronic said. Globally, the company said Hugo procedure growth is running at more than two times the robotic surgery market and is on track to exceed 50,000 procedures by the end of the company’s fiscal year. General surgery is the highest growth area, surpassing urology and gynecology.

"Hugo expands choice with a practical option to help hospitals address capacity and access challenges, while giving surgical teams more flexibility to meet patients' needs across care settings," Matt Anderson, senior vice president and president of Medtronic's surgical business, said in a statement.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.